The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation
Journal of Psychopharmacology 2022 James Rucker, Lindsey Marwood, Riikka-Liisa Johanna Ajantaival et al. 101 citations
Background: Psilocybin, a psychoactive serotonin receptor partial agonist, has been reported to acutely reduce clinical symptoms of depressive disorders. Psilocybin’s effects on cognitive function have not been widely or systematically studied. Aim: The aim of this study was to explore the safety of simultaneous administration of psilocybin to healthy participants in the largest randomised...
DOI: 10.1177/02698811211064720 (opens in new tab)
Psilocybin
Placebo
Adverse effect
Randomized controlled trial
+2